Exagen Inc. Common Stock (XGN) Stock
NASDAQ · XGN
8.54
Fundamentals
Market cap
$211.24M
Price / Earnings ratio
-11.2x
Price / Sales ratio
3.0x
Price / Book ratio
17.3x
Return on assets
-35.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Exagen Q2 Earnings Call Highlights
NeutralXGNAugust 4, 2026
MarketBeatNeutral
Exagen Q2 Earnings Call Highlights
XGN

Zacks Investment Research
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
NeutralXGNAugust 4, 2026
Zacks Investment ResearchNeutral
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
XGN

Zacks Investment Research
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
NeutralXGNMay 28, 2026
Zacks Investment ResearchNeutral
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
XGN

MarketBeat
Exagen Q1 Earnings Call Highlights
NeutralXGNMay 11, 2026
MarketBeatNeutral
Exagen Q1 Earnings Call Highlights
XGN
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 7 articles
published over the past 14 days
Latest news

MarketBeat
Exagen Q2 Earnings Call Highlights
NeutralXGNAugust 4, 2026
MarketBeatNeutral
Exagen Q2 Earnings Call Highlights
XGN

Zacks Investment Research
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
NeutralXGNAugust 4, 2026
Zacks Investment ResearchNeutral
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
XGN

Zacks Investment Research
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
NeutralXGNMay 28, 2026
Zacks Investment ResearchNeutral
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
XGN

MarketBeat
Exagen Q1 Earnings Call Highlights
NeutralXGNMay 11, 2026
MarketBeatNeutral
Exagen Q1 Earnings Call Highlights
XGN

Zacks Investment Research
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
NeutralXGNMay 11, 2026
Zacks Investment ResearchNeutral
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
XGN

Zacks Investment Research
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
NeutralXGNApril 28, 2026
Zacks Investment ResearchNeutral
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
XGN

Benzinga
Time to Play 5 Top-Ranked Stocks With Rising P/E?
NeutralXGNJune 10, 2024
BenzingaNeutral
Time to Play 5 Top-Ranked Stocks With Rising P/E?
XGN
About Exagen Inc. Common Stock
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
SectorHealthcare
IndustryDiagnostics & Research
Employees216
CEOMr. John Aballi
IPO DateSep 19, 2019
HeadquartersVista, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Tina S. Nova Ph.D. | Executive Chairman of the Board of Directors | 1954 |
| Mr. John Aballi | CEO, President & Director | 1985 |
| Mr. Jeffrey G. Black | CFO & Corporate Secretary | 1969 |
| Dr. Michael Mahler | Chief Scientific Officer | — |
| Ms. Tina Jacobsen CFA | Vice President of Investor Relations | — |
| Dr. Prashanti Reddy M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Market cap$211.24M
Price-to-sales ratio2.98
Price-to-book value17.33
Price-earnings ratio-11.20
Return on Equity-114.00%
Return on Sales-22.00%
Return on Assets-35.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.81
Income Statement
Average volume257,562
EBITDA$-11.77M
1 year high (52w)$12.23
1 year low (52w)$2.59
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$10.33
Est return
19.46%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +42.7 | -13.1 | -3.8 | +56.8 | +22.5 |



